Skip to main content

Table 2 Clinical features of 9 patients with GCK-MODY from south China

From: Genetic and clinical characteristics of Chinese children with Glucokinase-maturity-onset diabetes of the young (GCK-MODY)

Patients

Case 1

Case 2

Case 3

Case 4

Case5

Case 6

Case 7

Case 8

Case9

At diagnosis

 Age

1 m

3 m

1 m

6 y11 m

9 y1m

2 y9m

4y8m

8 y11m

8 y6 m

 Gender

M

M

F

F

F

M

M

M

M

 Gestational age(w + d)

38 + 1

37 + 6

34 + 6

38 + 4

39 + 1

38 + 6

37 + 5

37 + 5

38

 Birth weight (kg)

2.7

2.7

1.4

3.5

3.5

3.3

2.6

3.15

2.5

 Family history of diabetes

Father

Father/

Grandmother

Mother

Mother

Mother

Mother/

Grandfather

Father

Mother/

Grandmother

Father/

Grandfather

 BMI percentile

50th

25th

No data

25th

50th

25th

75th

50th

50th

 FPG (mmol/L)

8.5

7.2

6.5

6.8

6.1

7.1

7.3

7.1

7.2

 OGTT 2hPG (mmol/L)

No data

8.0

9.6(at 3 m)

7.8

7.6

7.6

8.4

8.2

8.8

 2hPG increment (mmol/L)

No data

0.8

3.1

1.0

1.5

0.5

1.1

1.1

1.6

 HbA1c (%/mmol/mol)

5.8/39.9

5.2/33.3

4.6/26.8(at 3 m)

5.7/38.8

5.8/39.9

5.9/41.0

6.6/48.6

6.5/47.5

6.7/49.7

 Fasting Ins (pmol/L)

30.5

29.7

13.1

30.9

31.5

24.9

15.1

7.8

23.5

 DKA

no

no

no

no

no

no

no

no

no

 Pancreatic autoantibody

negative

negative

negative

negative

negative

negative

negative

negative

negative

 Urine sugar

negative

negative

negative

negative

negative

negative

negative

negative

negative

 Other problems

      

EP at 2y

  

 Treatment and evolution

Diet, active exercise

Glibenclamide 0.3 mg/kg/d, stopped at 1y4m

Diet

Diet, active exercise

Diet, active exercise

Diet, active

Exercise

Diet, active exercise

Diet, active

Exercise

Diet, active exercise

Recent Follow-up

 Duration of follow-up

5 y

2 y 4 m

2 y1m

2 y6 m

1 y10 m

2 y

1 y1 m

9 m

4 y

 Age

5 y1 m

2 y7m

2 y2 m

9 y5 m

10 y11 m

4 y9 m

5 y9 m

9y8 m

12 y6 m

 BMI percentile

50th

25th

50th

50th

25th

25th

85th

50th

50th

 HbA1c (%/mmol/mol)

6.0/42.1

6.4/46.4

6.1/43.2

5.8/39.9

5.9/41.0

6.0/42.1

6.4/46.4

6.5/47.5

7.5/58.4

 FPG (mmol/L)

7.6

6.5

6.5

6.1

6.4

6.9

7.5

6.7

8.0

 Fasting Ins (pmol/L)

13.9

10.4

0.99

8.6

14.9

16.6

5.9

9.2

6.7

 OGTT 2hPG (mmol/L)

8.7

6.7

8.0

7.4

9.9

8.7

8.9

8.8

12.6

 2hPG increment (mmol/L)

1.1

0.2

1.5

1.3

3.5

1.8

1.4

2.1

4.6

 OGTT 2 h Ins (pmol/L)

90.6

19.4

23.8

43.9

61.4

47.9

32.9

49.6

52.1

 Combined with other problems

  

Developmental delay

   

EP and MR, treated with levetiracetam

  
  1. m month, y year, M male, F female, BMI body mass index, FPG fasting plasma glucose, PG plasma glucose, 2 h 2 h, Ins insulin, DKA diabetic ketoacidosis, OGTT oral glucose tolerance test, EP epilepsy, MR mental retardation